Overview

• At the top 36 mg dose, participants lost an average of 22.9 pounds, or 10.5% of body weight, after 72 weeks of once-daily orforglipron.
• The trial also showed an average A1C reduction of 1.8% in people with type 2 diabetes.
• Reported side effects were generally mild to moderate and similar to injectable GLP-1s, with upset stomach most commonly noted.
• Lilly has already begun mass production of orforglipron tablets to prepare for potential demand.
• The pill would enter a crowded field that includes Novo Nordisk’s oral Wegovy under FDA review and offers dosing without the fasting restrictions of Rybelsus.